Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: Results from a double-blind, randomized, placebo-controlled study

Critical Care Medicine

Volumn 24, Issue 2, 1996, Pages 207-214

  Zeni, Fabrice ^a   Pain, Pascal ^a   Vindimian, Monique ^a   Gay, Jean Pierre ^a   Gery, Pierre ^a   Bertrand, Monique ^a   Page, Yves ^a   Page, Dominique ^a   Vermesch, Regine ^a   Bertrand, Jean Claude ^a  

^a SERVICE DE NEUROLOGIE   (France)

Author keywords

critical illness; cytokines; hemodynamics; interleukin 6; interleukin 8; pentoxifylline; sepsis; septic shock; tumor necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODYNAMIC MONITORING; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OXYGENATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; PENTOXIFYLLINE; PROSPECTIVE STUDIES; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 9044224023     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199602000-00005     Document Type: Article

References (46)

1. Ziegler EJ, Fischer CJ, Sprung C, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
2. Fischer CJ, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokines levels in patients with sepsis. Crit Care Med 1993; 21:318-327
3. Fisher CJ Jr, Slotman GJ, Opal SM, et al: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-contolled multicenter trial. Crit Care Med 1994; 22:12-21
4. Dhainaut JF, Tenaillon A, Letulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22:1720-1728
5. Ward A, Clissold SP: Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 1987; 34:50-97
6. Schade UF: Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31:171-181
7. Noel P, Nelson S, Bokulic R, et al: Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 1990; 47:1023-1029
8. Borens KL, Langston JD, Wasan KM, et al: Influence of pentoxifylline and related analogs in endotoxic renal failure. Circ Shock 1991; 34:344-348
9. Betticher DC, Keller H, Malvy FE, et al: The effect of endotoxin and tumour necrosis factor on erythrocyte and leucocyte deformability in vitro. Br J Haematol 1993; 83:130-137
10. Schroer R: Antithrombotic potential of pentoxifylline, a hemorrheologically active drug. Angiology 1985; 36:387-398
11. Doherty GM, Jensen JC, Alexander R, et al: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991; 110:192-198
12. Zabel P, Wolter DT, Schonharting MM, et al: Oxpentifylline in endotoxaemia. Lancet 1989; ii:1474-1477
13. Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 1987; 316:379-385
14. Strieter RM, Remick DG, Ward PA, et al: Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155:1230-1236
15. Sullivan GW, Carper HT, Novick WJ, et al: Inhibition of the inflammatory action of interleukin 1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 1988; 7:1722-1729
16. Crouch SPM, Fletcher J: Effect of ingested pentoxifylline on neutrophil superoxide anion production. Infect Immun 1992; 60:4504-4509
17. Ishizaka A, Wu Z, Stephens KE, et al: Attenuation of acute lung injury in septic guinea pigs by pentoxifylline. Am Rev Respir Dis 1988; 138:376-382
18. Tighe D, Moss R, Hynd J, et al: Pre-treatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit Care Med 1990; 18:184-189
19. Harada H, Ishizaka A, Yonemaru M, et al: The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis 1989; 140:974-980
20. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
21. Le Gall JR, Loirat P, Alperovitch D, et al: A simplified acute physiology score for ICU patients. Crit Care Med 1984; 12:975-977
22. Mac Cabe WR, Jackson GC: Gram-negative bacteremia clinical, laboratory, and therapeutic observations. Arch Intern Med 1962; 110:856-863
23. Garnier-Moiroux A, Poirier JM, Cheymol G, et al: High perfomance liquid chromatographic determination of pentoxifylline and its hydroxy metabolite in human plasma. J Chromatogr 1987; 416:183-188
24. Hesse DG, Tracey KJ, Fong Y: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166:147-153
25. Michie HR, Manogue KR, Spriggs DR, et al: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486
26. Girardin E, Grau GE, Dayer JM, et al: Tumor necrosis factor and Interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319:397-400
27. Debets JMH, Kampmeijer R, Van Der Linden MPMH, et al: Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17:489-494
28. Calandra T, Baumgartner JD, Grau GE, et al: Prognosis values of Tumor necrosis factor/cachectin, Interleuklin-1, alpha-interferon and gamma-interferon in the serum of patients with septic shock. J Infect Dis 1990; 161:982-87
29. Marks J, Marks CB, Luce J, et al: Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 1990; 141:94-97
30. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474
31. Bauss F, Drage W, Mannel DN: Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun 1987; 55:1622-1625
32. Beutler B, Milsark IW, Cerami A: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-871
33. Mathison JC, Wolfson E, Ulevitch RJ: Participation of tumor necrosis factor in the mediation of Gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925-1937
34. Tracey KJ, Fong Y, Hesse D, et al: Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330:662-664
35. Bagby GJ, Plessala KJ, Wilson LA, et al: Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163:83-88
36. Nakane A, Minagawa T, Kato K: Endogenous tumor necrosis factor (cachectin) is essential host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56:2563-2569
37. Gibson RL, Redding GJ, Henderson WR, et al: Group B Streptococcus induces tumor necrosis factor in neonatal piglets. Am Rev Respir Dis 1991; 143: 598-604
38. Lechner AJ, Rouben LR, Potthoff LH, et al: Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock. Circ Shock 1993; 39:306-315
39. Quezado ZMN, Natanson C, Banks SM, et al: Pentoxifylline can increase tumor necrosis factor level and decrease survival in a canine model of Gram-negative septic shock. Abstr. Crit Care Med 1993; 21(Suppl):S281
40. Martich GD, Danner RL, Ceska M, et al: Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effects of anti-inflammatory agents. J Exp Med 1991; 173:1021-1024
41. Leimenstoll G, Zabel P, Schroder P, et al: Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients. Transplant Proc 1993; 25:561-563
42. Zheng H, Crowley JJ, Chan CG, et al: Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminescence. Am Rev Respir Dis 1990; 142:1073-1078
43. Sato K, Stelzner TJ, O'Brien RF, et al: Pentoxifylline lessens the endotoxin induced increase in albumine clearance across pulmonary artery endothelial monolayers with and without neutrophils. Am J Respir Cell Mol Biol 1991; 4:219-227
44. Heidrich H, Paeprer M, Barckow D, et al: The effect of pentoxifylline on central and peripheral haemodynamics - An experimental clinical study. Z Kardiol 1976; 65:385-391
45. Fletcher MA, McKenna TM, Owens EH, et al: Effects of in vivo pentoxifylline treatment on survival and ex vivo vascular contractility in a rat lipopolysaccharide shock model. Circ Shock 1992; 36:74-80
46. Montravers P, Fagon JY, Gibert C, et al: Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest 1993; 103: 1017-1022